Year: 2016
Type: article
Study design: Observational Study
Abstract: Background. Patients with chronic hepatitis C virus (HCV) infection may be prescribed statins for metabolic/cardiovascular disease, but it remains unclear if the risk of acute liver injury (ALI) associated with statin use is higher for chronic HCV-infected persons. Methods. We conducted a cohort study among 3768 chronic HCV-infected statin initiators, 23,535 HCV-uninfected statin initiators, 12,073 chronic HCV-infected statin non-users, and 30,808 HCV-uninfected statin non-users in the Veterans Aging Cohort Study from 2000 to 2012. We determined development of (1) liver aminotransferases >200 U/L, (2) severe ALI (international normalized ratio 31.5 and total bilirubin >2 times upper limit of normal [ULN]), (3) hospitalization with an ALI diagnosis, and (4) all-cause mortality. Cox regression was used to determine propensity score-adjusted hazard ratios (HRs) with 95% confidence intervals (CIs). Results. Chronic HCV-infected statin initiators had higher risks of liver aminotransferases >200U/L, severe ALI, hospitalization with ALI, and death, than HCV-uninfected statin initiators. In contrast, HCV-infected statin initiators had lower risks of liver aminotransferases >200 U/L, severe ALI, hospitalization with severe ALI, and death compared those HCV-infected not using statins. The risk of death was lower for HCV-infected statin initiators than HCV-uninfected statin non-users. Table 1: Propensity Score-Adjusted Relative Hazards of Specified Outcomes Conclusion. Chronic HCV-infected statin initiators had a higher risk of ALI events and death than HCV-uninfected statin initiators but a lower risk of ALI outcomes and death than chronic HCV-infected statin non-users and lower risk of death than HCV-uninfected statin non-users. Disclosures. J. R. Kostman, Gilead Sciences: Scientific Advisor, Consulting fee; V. Lo Re III, AstraZeneca: Grant Investigator, Research grant. Gilead Sciences: Grant Investigator, Research grant
Source: Open Forum Infectious Diseases
Language: English
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,053
OpenAlex ID: W2564583170